Congestive Heart Failure Drugs Market

Congestive Heart Failure Drugs Market (Type of Congestive Heart Failure: Left-sided Heart Failure, Right-sided Heart Failure, and High-output Heart Failure) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Global Congestive Heart Failure Drugs Market Outlook 2031

  • The global industry was valued at US$ 6.7 Bn in 2022
  • It is projected to grow at a CAGR of 7.6% from 2023 to 2031 and reach more than US$ 13.5 Bn by the end of 2031

Analysts’ Viewpoint

Increase in the geriatric population and rise in prevalence of diabetes, obesity, and hypertension are driving the global congestive heart failure drugs market. Poor diet, sedentary lifestyle, and tobacco consumption could increase the risk of developing congestive heart failure (CHF). Furthermore, rise in healthcare expenditure, increase in awareness about heart health, and surge in access to healthcare services are expected to bolster market expansion during the forecast period.

Development of innovative treatments and technologies, such as implantable devices and stem cell therapy, for the treatment of CHF offers lucrative opportunities to market players. Manufacturers are focusing on launch of efficient and low cost products and services such as medications, medical devices, and surgical procedures to increase market share.

Congestive Heart Failure Drugs Market

Congestive Heart Failure Drugs Market Introduction

Congestive heart failure is a chronic condition, where the heart cannot pump enough blood to meet the body's needs. CHF drugs are used to manage the symptoms and improve the quality of life of patients. Major drug classes used to treat CHF are diuretics, ACE inhibitors, ARBs, beta-blockers, aldosterone antagonists, and digitalis. These drugs work by reducing the workload on the heart, improving blood flow, and preventing the buildup of fluid in the lungs and other parts of the body.

Rise in Prevalence of Heart Failure

Heart failure, also known as congestive heart failure, is a medical condition, in which the heart is unable to pump enough blood to meet the body's needs. It is a chronic and progressive condition that affects millions of people globally. According to the American Heart Association, the prevalence of heart failure is increasing, and affects nearly 6.5 million people aged 20 years and older in the U.S. Rise in the prevalence of heart failure is propelling the global congestive heart failure market size.

Aging population is another factor contributing to surging in prevalence of heart failure. Risk of developing heart failure increases as people age. The aging baby boomer population, in particular, is expected to contribute significantly to rise in prevalence of heart failure. Increase in incidence of obesity and diabetes is another factor contributing to rising in the prevalence of heart failure.

Technological Advancements in Drug Development

Technological advancements in drug development are driving the global congestive heart failure drugs market. These advancements are enabling the identification of new drug targets and biomarkers for CHF, which could lead to development of more effective and targeted therapies. For instance, advances in genetics and molecular biology have enabled researchers to identify specific genes, proteins, and signaling pathways involved in the development and progression of congestive heart failure. This has led to the development of drugs that target these specific molecules or pathways, such as angiotensin receptor blockers, which affect the renin-angiotensin system.

Technological advancements are improving drug discovery and development processes. High-throughput screening methods, which use robotics and automation to quickly test large number of compounds, have accelerated the drug discovery process. Advances in computational modeling and simulation are helping researchers to design and optimize drug candidates more efficiently, thereby reducing the time and costs involved in drug development.

Technological advancements are also enhancing the delivery of congestive heart failure drugs to patients. Development of nanotechnology-based drug delivery systems has enabled targeted delivery of drugs to specific tissues or cells, thus improving drug efficacy and reducing side effects. Furthermore, usage of implantable devices such as pacemakers and implantable cardioverter-defibrillators (ICDs) are helping to manage the symptoms of congestive heart failure and reduce the risk of sudden cardiac death.

Severe Symptoms and Complications Associated with Left-sided Heart Failure

In terms of type of congestive heart failure, the left-sided heart failure segment accounted for largest global congestive heart failure drugs market share in 2022. This is ascribed to higher prevalence compared to right-sided heart failure. Additionally, left-sided heart failure can lead to more severe symptoms and complications, which could require more aggressive treatment with medication.

High Adoption of ACE Inhibitors Due to Low Risk of Side Effects

Based on drug class, the ACE inhibitors segment dominated the global market in 2022. ACE inhibitors are highly effective in reducing the symptoms and progression of the disease. Numerous clinical trials have shown that ACE inhibitors can reduce hospitalizations and mortality rates in CHF patients. These are also well-tolerated and have a relatively low risk of side effects compared to other CHF drugs. ACE inhibitors are available in generic forms, which are much cheaper than branded drugs, making them accessible to a wider patient population. Additionally, long-term usage of ACE inhibitors is cost-effective, as these can help prevent hospitalization and other expensive medical procedures associated with CHF.

Easy Access Driving Retail Pharmacies Segment

In terms of distribution channel, the retail pharmacies segment held the leading share of the global congestive heart failure drugs market in 2022. Retail pharmacies are easily accessible to patients and are spread across various geographies. This makes it convenient for CHF patients to purchase medications easily and regularly, without having to travel far or face any logistical difficulties.

Retail pharmacies offer a range of CHF medications from different manufacturers, giving patients the opportunity to compare prices and choose the most affordable option. These channels have strong relationships with health insurance providers, which enables them to provide patients with insurance coverage information, co-pay assistance programs, and other cost-saving measures. This can be a significant advantage for CHF patients, as the cost of medication can be a major barrier to accessing and adhering to treatment.

Regional Outlook

As per congestive heart failure drugs industry trends, North America accounted for the leading share of the global market in 2022. This is ascribed to high prevalence of heart diseases, well-developed healthcare infrastructure, and increase in investment in research & development activities in the region. According to the Centers for Disease Control and Prevention (CDC), cardiovascular diseases claim the life of one individual in the U.S. every 34 seconds. Furthermore, heart diseases accounted for approximately 697,000 deaths in the country in 2020, which equates to one in every five fatalities.

The market is Europe is driven by surge in prevalence of CHF, aging population, and development of novel therapies. Pharmaceutical companies are investing significantly in research & development to bring innovative therapies and drugs to market. For example, Entresto, a novel drug developed by Novartis, has been shown to improve patient outcomes in clinical trials and has received regulatory approval in Europe. Additionally, there has been a growing interest in precision medicine for CHF, with the usage of biomarkers and genetic testing to tailor treatments to individual patients.

Analysis of Key Players

The global market is fragmented, with the presence of large number of players. Companies in the congestive heart failure drugs market are Bayer AG, Novartis AG, Merck & Co., Inc., AstraZeneca, Bristol-Myers Squibb Company, Amgen, Inc., Boehringer Ingelheim International GmbH., Pfizer, Inc., Johnson & Johnson Services, Inc., and Eli Lilly and Company. Major players have adopted strategies such merger & acquisition, collaboration, and portfolio expansion to increase market share and presence.

Key Developments in Global Congestive Heart Failure Drugs Industry

  • In February 2021, Novartis announced that the U.S. Food and Drug Administration (FDA) granted approval for an expanded indication of Entresto (sacubitril/valsartan). The medication is now approved to decrease the likelihood of cardiovascular death and hospitalization for adult patients suffering from chronic heart failure. Advantages of the medication are most apparent in patients with left ventricular ejection fraction (LVEF) that is below the normal range.
  • In January 2021, Merck declared that VERQUVO, a soluble guanylate cyclase stimulator, has been sanctioned by the U.S. Food and Drug Administration (FDA) to lessen the likelihood of cardiovascular mortality and hospitalization due to heart failure in adults suffering from symptomatic chronic heart failure with an ejection fraction less than 45%, subsequent to hospitalization for heart failure or the requirement for intravenous diuretics on an outpatient basis.

Each of these players in the congestive heart failure drugs market has been profiled in the report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Global Congestive Heart Failure Drugs Market Snapshot

Attribute

Detail

Size in 2022

US$ 6.7 Bn

Forecast (Value) in 2031

More than US$ 13.5 Bn

CAGR

7.6%

Forecast Period

2023–2031

Historical Data Available for

2017–2021

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.

Competition Landscape

  • Market share analysis by company (2022)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Segmentation

  • Type of Congestive Heart Failure
    • Left-sided Heart Failure
    • Right-sided Heart Failure
    • High-output Heart Failure
  • Drug Class
    • ACE Inhibitors (dominated)
    • Angiotensin-2 Receptor Blockers (ARBs or AIIRAs)
    • Beta Blockers
    • Mineralocorticoid Receptor Antagonists
    • Diuretics
    • Ivabradine
    • Sacubitril Valsartan
    • Others (digoxin, etc.)
  • Distribution Channel
    • Hospitals Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • Bayer AG
  • Novartis AG
  • Merck & Co., Inc.
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • Amgen, Inc.
  • Boehringer Ingelheim International GmbH
  • Pfizer, Inc.
  • Johnson & Johnson Services, Inc.
  • Eli Lilly and Company

Frequently Asked Questions

How big was the global congestive heart failure drugs market in 2022?

The global industry was valued at US$ 6.7 Bn in 2022

How big will be the congestive heart failure drugs market size in 2031?

It is projected to reach more than US$ 13.5 Bn by 2031

What will be the CAGR during the forecast period?

The CAGR is anticipated to be 7.6% from 2023 to 2031

What was the share of the leading segment?

The ACE inhibitors segment held more than 50.0% share in 2022

Which region will account for major share during the forecast period?

North America is expected to account for significant share from 2022 to 2031

Who are the prominent players in the congestive heart failure drugs business?

Bayer AG, Novartis AG, Merck & Co., Inc., AstraZeneca, Bristol-Myers Squibb Company, Amgen, Inc., Boehringer Ingelheim International GmbH., Pfizer, Inc., Johnson & Johnson Services, Inc., and Eli Lilly and Company are the prominent players in the market.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Congestive Heart Failure Drugs Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Segment Definition

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Congestive Heart Failure Drugs Market Analysis and Forecast, 2017–2031

            4.4.1. Market Revenue Projections (US$ Mn)

    5. Key Insights

        5.1. Key Industry Events

        5.2. Pipeline Analysis

        5.3. Heart Failure Diseases Prevalence: Overview

    6. Global Congestive Heart Failure Drugs Market Analysis and Forecast, by Type of Digestive Heart Failure

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast, by Type of Digestive Heart Failure, 2017–2031

            6.3.1. Left-sided Heart Failure

            6.3.2. Right-sided Heart Failure

            6.3.3. High-output Heart Failure

        6.4. Market Attractiveness Analysis, by Type of Digestive Heart Failure

    7. Global Congestive Heart Failure Drugs Market Analysis and Forecast, by Drug Class

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Market Value Forecast, by Drug Class, 2017–2031

            7.3.1. ACE Inhibitors

            7.3.2. Angiotensin-2 Receptor Blockers

            7.3.3. Beta Blockers

            7.3.4. Mineralocorticoid Receptor Antagonists

            7.3.5. Diuretics

            7.3.6. Ivabradine

            7.3.7. Sacubitril Valsartan

            7.3.8. Others (digoxin etc.)

        7.4. Market Attractiveness Analysis, by Drug Class

    8. Global Congestive Heart Failure Drugs Market Analysis and Forecast, by Distribution Channel

        8.1. Introduction & Definition

        8.2. Key Findings / Developments

        8.3. Market Value Forecast, by Distribution Channel, 2017–2031

            8.3.1. Hospitals Pharmacies

            8.3.2. Retail Pharmacies

            8.3.3. Online Pharmacies

        8.4. Market Attractiveness Analysis, by Distribution Channel

    9. Global Congestive Heart Failure Drugs Market Analysis and Forecast, by Region

        9.1. Key Findings

        9.2. Market Value Forecast, by Region

            9.2.1. North America

            9.2.2. Europe

            9.2.3. Asia Pacific

            9.2.4. Latin America

            9.2.5. Middle East & Africa

        9.3. Market Attractiveness Analysis, by Region

    10. North America Congestive Heart Failure Drugs Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast, by Type of Digestive Heart Failure, 2017–2031

            10.2.1. Left-sided Heart Failure

            10.2.2. Right-sided Heart Failure

            10.2.3. High-output Heart Failure

        10.3. Market Value Forecast, by Drug Class, 2017–2031

            10.3.1. ACE Inhibitors

            10.3.2. Angiotensin-2 Receptor Blockers

            10.3.3. Beta Blockers

            10.3.4. Mineralocorticoid Receptor Antagonists

            10.3.5. Diuretics

            10.3.6. Ivabradine

            10.3.7. Sacubitril Valsartan

            10.3.8. Others (digoxin etc.)

        10.4. Market Value Forecast, by Distribution Channel, 2017–2031

            10.4.1. Hospitals Pharmacies

            10.4.2. Retail Pharmacies

            10.4.3. Online Pharmacies

        10.5. Market Value Forecast, by Country, 2017–2031

            10.5.1. U.S.

            10.5.2. Canada

        10.6. Market Attractiveness Analysis

            10.6.1. By Type of Digestive Heart Failure

            10.6.2. By Drug Class

            10.6.3. By Distribution Channel

            10.6.4. By Country

    11. Europe Congestive Heart Failure Drugs Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Type of Digestive Heart Failure, 2017–2031

            11.2.1. Left-sided Heart Failure

            11.2.2. Right-sided Heart Failure

            11.2.3. High-output Heart Failure

        11.3. Market Value  Forecast, by Drug Class, 2017–2031

            11.3.1. ACE Inhibitors

            11.3.2. Angiotensin-2 Receptor Blockers

            11.3.3. Beta Blockers

            11.3.4. Mineralocorticoid Receptor Antagonists

            11.3.5. Diuretics

            11.3.6. Ivabradine

            11.3.7. Sacubitril Valsartan

            11.3.8. Others (digoxin etc.)

        11.4. Market Value Forecast, by Distribution Channel, 2017–2031

            11.4.1. Hospitals Pharmacies

            11.4.2. Retail Pharmacies

            11.4.3. Online Pharmacies

        11.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            11.5.1. Germany

            11.5.2. U.K.

            11.5.3. France

            11.5.4. Italy

            11.5.5. Spain

            11.5.6. Rest of Europe

        11.6. Market Attractiveness Analysis

            11.6.1. By Type of Digestive Heart Failure

            11.6.2. By Drug Class

            11.6.3. By Distribution Channel

            11.6.4. By Country/Sub-region

    12. Asia Pacific Congestive Heart Failure Drugs Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Type of Digestive Heart Failure, 2017–2031

            12.2.1. Left-sided Heart Failure

            12.2.2. Right-sided Heart Failure

            12.2.3. High-output Heart Failure

        12.3. Market Value  Forecast, by Drug Class, 2017–2031

            12.3.1. ACE Inhibitors

            12.3.2. Angiotensin-2 Receptor Blockers

            12.3.3. Beta Blockers

            12.3.4. Mineralocorticoid Receptor Antagonists

            12.3.5. Diuretics

            12.3.6. Ivabradine

            12.3.7. Sacubitril Valsartan

            12.3.8. Others (digoxin etc.)

        12.4. Market Value Forecast, by Distribution Channel, 2017–2031

            12.4.1. Hospitals Pharmacies

            12.4.2. Retail Pharmacies

            12.4.3. Online Pharmacies

        12.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            12.5.1. China

            12.5.2. Japan

            12.5.3. India

            12.5.4. Australia & New Zealand

            12.5.5. Rest of Asia Pacific

        12.6. Market Attractiveness Analysis

            12.6.1. By Type of Digestive Heart Failure

            12.6.2. By Drug Class

            12.6.3. By Distribution Channel

            12.6.4. By Country/Sub-region

    13. Latin America Congestive Heart Failure Drugs Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Type of Digestive Heart Failure, 2017–2031

            13.2.1. Left-sided Heart Failure

            13.2.2. Right-sided Heart Failure

            13.2.3. High-output Heart Failure

        13.3. Market Value Forecast, by Drug Class, 2017–2031

            13.3.1. ACE Inhibitors

            13.3.2. Angiotensin-2 Receptor Blockers

            13.3.3. Beta Blockers

            13.3.4. Mineralocorticoid Receptor Antagonists

            13.3.5. Diuretics

            13.3.6. Ivabradine

            13.3.7. Sacubitril Valsartan

            13.3.8. Others (digoxin etc.)

        13.4. Market Value Forecast, by Distribution Channel, 2017–2031

            13.4.1. Hospitals Pharmacies

            13.4.2. Retail Pharmacies

            13.4.3. Online Pharmacies

        13.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            13.5.1. Brazil

            13.5.2. Mexico

            13.5.3. Rest of Latin America

        13.6. Market Attractiveness Analysis

            13.6.1. By Type of Digestive Heart Failure

            13.6.2. By Drug Class

            13.6.3. By Distribution Channel

            13.6.4. By Country/Sub-region

    14. Middle East & Africa Congestive Heart Failure Drugs Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast, by Type of Digestive Heart Failure, 2017–2031

            14.2.1. Left-sided Heart Failure

            14.2.2. Right-sided Heart Failure

            14.2.3. High-output Heart Failure

        14.3. Market Value  Forecast, by Drug Class, 2017–2031

            14.3.1. ACE Inhibitors

            14.3.2. Angiotensin-2 Receptor Blockers

            14.3.3. Beta Blockers

            14.3.4. Mineralocorticoid Receptor Antagonists

            14.3.5. Diuretics

            14.3.6. Ivabradine

            14.3.7. Sacubitril Valsartan

            14.3.8. Others (digoxin etc.)

        14.4. Market Value Forecast, by Distribution Channel, 2017–2031

            14.4.1. Hospitals Pharmacies

            14.4.2. Retail Pharmacies

            14.4.3. Online Pharmacies

        14.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            14.5.1. GCC Countries

            14.5.2. South Africa

            14.5.3. Rest of Middle East & Africa

        14.6. Market Attractiveness Analysis

            14.6.1. By Type of Digestive Heart Failure

            14.6.2. By Drug Class

            14.6.3. By Distribution Channel

            14.6.4. By Country/Sub-region

    15. Competition Landscape

        15.1. Market Player - Competition Matrix (by tier and size of companies)

        15.2. Market Share Analysis, by Company, 2021

        15.3. Company Profiles

            15.3.1. Bayer AG

                15.3.1.1. Company Overview

                15.3.1.2. Financial Overview

                15.3.1.3. Product Portfolio

                15.3.1.4. Business Strategies

                15.3.1.5. Recent Developments

            15.3.2. Novartis AG

                15.3.2.1. Company Overview

                15.3.2.2. Financial Overview

                15.3.2.3. Product Portfolio

                15.3.2.4. Business Strategies

                15.3.2.5. Recent Developments

            15.3.3. Merck & Co., Inc.

                15.3.3.1. Company Overview

                15.3.3.2. Financial Overview

                15.3.3.3. Product Portfolio

                15.3.3.4. Business Strategies

                15.3.3.5. Recent Developments

            15.3.4. AstraZeneca

                15.3.4.1. Company Overview

                15.3.4.2. Financial Overview

                15.3.4.3. Product Portfolio

                15.3.4.4. Business Strategies

                15.3.4.5. Recent Developments

            15.3.5. Bristol-Myers Squibb Company

                15.3.5.1. Company Overview

                15.3.5.2. Financial Overview

                15.3.5.3. Product Portfolio

                15.3.5.4. Business Strategies

                15.3.5.5. Recent Developments

            15.3.6. Amgen, Inc.

                15.3.6.1. Company Overview

                15.3.6.2. Financial Overview

                15.3.6.3. Product Portfolio

                15.3.6.4. Business Strategies

                15.3.6.5. Recent Developments

            15.3.7. Boehringer Ingelheim International GmbH

                15.3.7.1. Company Overview

                15.3.7.2. Financial Overview

                15.3.7.3. Product Portfolio

                15.3.7.4. Business Strategies

                15.3.7.5. Recent Developments

            15.3.8. Pfizer, Inc.

                15.3.8.1. Company Overview

                15.3.8.2. Financial Overview

                15.3.8.3. Product Portfolio

                15.3.8.4. Business Strategies

                15.3.8.5. Recent Developments

            15.3.9. Johnson & Johnson Services, Inc.

                15.3.9.1. Company Overview

                15.3.9.2. Financial Overview

                15.3.9.3. Product Portfolio

                15.3.9.4. Business Strategies

                15.3.9.5. Recent Developments

            15.3.10. Eli Lilly and Company

                15.3.10.1. Company Overview

                15.3.10.2. Financial Overview

                15.3.10.3. Product Portfolio

                15.3.10.4. Business Strategies

                15.3.10.5. Recent Developments

    List of Tables

    Table 01: Global Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Type Congestive Heart Failure Drugs, 2017‒2031

    Table 02: Global Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

    Table 03: Global Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 04: Global Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Region, 2017–2031

    Table 05: North America Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Country, 2017–2031

    Table 06: North America Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Type Congestive Heart Failure Drugs, 2017‒2031

    Table 07: North America Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

    Table 08: North America Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 09: Europe Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 10: Europe Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Type Congestive Heart Failure Drugs, 2017‒2031

    Table 11: Europe Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

    Table 12: Europe Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 13: Asia Pacific Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 14: Asia Pacific Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Type Congestive Heart Failure Drugs, 2017‒2031

    Table 15: Asia Pacific Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

    Table 16: Asia Pacific Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 17: Latin America Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 18: Latin America Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Type Congestive Heart Failure Drugs, 2017‒2031

    Table 19: Latin America Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

    Table 20: Latin America Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 21: Middle East & Africa Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 22: Middle East & Africa Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Type Congestive Heart Failure Drugs, 2017‒2031

    Table 23: Middle East & Africa Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

    Table 24: Middle East & Africa Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    List of Figures

    Figure 01: Global Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, 2017–2031

    Figure 02: Global Congestive Heart Failure Drugs Market Value Share, by Type of Congestive Heart Failure, 2022

    Figure 03: Global Congestive Heart Failure Drugs Market Value Share, by Drug Class, 2022

    Figure 04: Global Congestive Heart Failure Drugs Market Value Share, by Distribution Channel, 2022

    Figure 05: Global Congestive Heart Failure Drugs Market Value Share Analysis, by Type of Congestive Heart Failure, 2022 and 2031

    Figure 06: Global Congestive Heart Failure Drugs Market Attractiveness Analysis, by Type of Congestive Heart Failure, 2023–2031

    Figure 07: Global Congestive Heart Failure Drugs Market Value (US$ Mn), by Left-sided Heart Failure, 2017‒2031

    Figure 08: Global Congestive Heart Failure Drugs Market Value (US$ Mn), by Right-sided Heart Failure, 2017‒2031

    Figure 09: Global Congestive Heart Failure Drugs Market Value (US$ Mn), by High-output Heart Failure, 2017‒2031

    Figure 10: Global Congestive Heart Failure Drugs Market Value Share Analysis, by Drug Class 2022 and 2031

    Figure 11: Global Congestive Heart Failure Drugs Market Attractiveness Analysis, by Drug Class 2023–2031

    Figure 12: Global Congestive Heart Failure Drugs Market Revenue (US$ Mn), by ACE Inhibitors, 2017–2031

    Figure 13: Global Congestive Heart Failure Drugs Market Revenue (US$ Mn), by Angiotensin-2 Receptor Blockers (ARBs or AIIRAs), 2017–2031

    Figure 14: Global Congestive Heart Failure Drugs Market Revenue (US$ Mn), by Beta Blockers, 2017–2031

    Figure 15: Global Congestive Heart Failure Drugs Market Revenue (US$ Mn), by Mineralocorticoid Receptor Antagonists, 2017–2031

    Figure 16: Global Congestive Heart Failure Drugs Market Revenue (US$ Mn), by Diuretics, 2017–2031

    Figure 17: Global Congestive Heart Failure Drugs Market Revenue (US$ Mn), by Ivabradine, 2017–2031

    Figure 18: Global Congestive Heart Failure Drugs Market Revenue (US$ Mn), by Sacubitril Valsartan, 2017–2031

    Figure 19: Global Congestive Heart Failure Drugs Market Revenue (US$ Mn), by others (digoxin etc.), 2017–2031

    Figure 20: Global Congestive Heart Failure Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 21: Global Congestive Heart Failure Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031

    Figure 22: Global Congestive Heart Failure Drugs Market Revenue (US$ Mn), by Hospitals Pharmacies, 2017–2031

    Figure 23: Global Congestive Heart Failure Drugs Market Revenue (US$ Mn), by Retail Pharmacies, 2017–2031

    Figure 24: Global Congestive Heart Failure Drugs Market Revenue (US$ Mn), by Online Pharmacies, 2017–2031

    Figure 25: Global Congestive Heart Failure Drugs Market Value Share Analysis, by Region, 2022 and 2031

    Figure 26: Global Congestive Heart Failure Drugs Market Attractiveness Analysis, by Region, 2023–2031

    Figure 27: North America Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, 2017–2031

    Figure 28: North America Congestive Heart Failure Drugs Market Value Share Analysis, by Country, 2022 and 2031

    Figure 29: North America Congestive Heart Failure Drugs Market Attractiveness Analysis, by Country, 2023–2031 

    Figure 30: North America Congestive Heart Failure Drugs Market Value Share Analysis, by Type of Congestive Heart Failure, 2022 and 2031

    Figure 31: North America Congestive Heart Failure Drugs Market Attractiveness Analysis, by Type of Congestive Heart Failure, 2023–2031

    Figure 32: North America Congestive Heart Failure Drugs Market Value Share Analysis, by Drug Class 2022 and 2031

    Figure 33: North America Congestive Heart Failure Drugs Market Attractiveness Analysis, by Drug Class 2023–2031

    Figure 34: North America Congestive Heart Failure Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 35: North America Congestive Heart Failure Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031

    Figure 36: Europe Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, 2017–2031

    Figure 37: Europe Congestive Heart Failure Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 38: Europe Congestive Heart Failure Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 39: Europe Congestive Heart Failure Drugs Market Value Share Analysis, by Type of Congestive Heart Failure, 2022 and 2031

    Figure 40: Europe Congestive Heart Failure Drugs Market Attractiveness Analysis, by Type of Congestive Heart Failure, 2023–2031

    Figure 41: Europe Congestive Heart Failure Drugs Market Value Share Analysis, by Drug Class 2022 and 2031

    Figure 42: Europe Congestive Heart Failure Drugs Market Attractiveness Analysis, by Drug Class 2023–2031

    Figure 43: Europe Congestive Heart Failure Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 44: Europe Congestive Heart Failure Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031

    Figure 45: Asia Pacific Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, 2017–2031

    Figure 46: Asia Pacific Congestive Heart Failure Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 47: Asia Pacific Congestive Heart Failure Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 48: Asia Pacific Congestive Heart Failure Drugs Market Value Share Analysis, by Type of Congestive Heart Failure, 2022 and 2031

    Figure 49: Asia Pacific Congestive Heart Failure Drugs Market Attractiveness Analysis, by Type of Congestive Heart Failure, 2023–2031

    Figure 50: Asia Pacific Congestive Heart Failure Drugs Market Value Share Analysis, by Drug Class 2022 and 2031

    Figure 51: Asia Pacific Congestive Heart Failure Drugs Market Attractiveness Analysis, by Drug Class 2023–2031

    Figure 52: Asia Pacific Congestive Heart Failure Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 53: Asia Pacific Congestive Heart Failure Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031

    Figure 54: Latin America Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, 2017–2031

    Figure 55: Latin America Congestive Heart Failure Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 56: Latin America Congestive Heart Failure Drugs Market Attractiveness Analysis, by Country/Sub-region, 2022-2031

    Figure 57: Latin America Congestive Heart Failure Drugs Market Value Share Analysis, by Type of Congestive Heart Failure, 2022 and 2031

    Figure 58: Latin America Congestive Heart Failure Drugs Market Attractiveness Analysis, by Type of Congestive Heart Failure, 2023–2031

    Figure 59: Latin America Congestive Heart Failure Drugs Market Value Share Analysis, by Drug Class 2022 and 2031

    Figure 60: Latin America Congestive Heart Failure Drugs Market Attractiveness Analysis, by Drug Class 2023–2031

    Figure 61: Latin America Congestive Heart Failure Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 62: Latin America Congestive Heart Failure Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031

    Figure 63: Middle East & Africa Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, 2017–2031

    Figure 64: Middle East & Africa Congestive Heart Failure Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 65: Middle East & Africa Congestive Heart Failure Drugs Market Attractiveness Analysis, by Country/Sub-region, 2022-2031

    Figure 66: Middle East & Africa Congestive Heart Failure Drugs Market Value Share Analysis, by Type of Congestive Heart Failure, 2022 and 2031

    Figure 67: Middle East & Africa Congestive Heart Failure Drugs Market Attractiveness Analysis, by Type of Congestive Heart Failure, 2023–2031

    Figure 68: Middle East & Africa Congestive Heart Failure Drugs Market Value Share Analysis, by Drug Class 2022 and 2031

    Figure 69: Middle East & Africa Congestive Heart Failure Drugs Market Attractiveness Analysis, by Drug Class 2023–2031

    Figure 70: Middle East & Africa Congestive Heart Failure Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 71: Middle East & Africa Congestive Heart Failure Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031

    Figure 72: Company Share Analysis, 2022

Copyright © Transparency Market Research, Inc. All Rights reserved